Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
Jim Gallagher2021 年 4 月 27 日
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021 年 4 月 21 日
Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021 年 4 月 21 日
Part 1: What are oligonucleotide therapeutics, and how do they work?
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021 年 4 月 21 日
Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure
The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…
Jim Gallagher2021 年 4 月 1 日
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
The extent of cross-protection provided by currently licensed bivalent and quadrivalent HPV vaccines versus direct…
Jim Gallagher2021 年 3 月 18 日
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
It is crucial for biotech developers to engage in early commercial market assessment to generate…
Jim Gallagher2021 年 3 月 5 日
BPS Article: Model‐Informed Drug Repurposing: a Pharmacometric Approach to Novel Pathogen Preparedness, Response and Retrospection
Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential…
Certara2021 年 2 月 9 日
How drug developers can avoid these common mistakes to secure a deal
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
Jim Gallagher2021 年 1 月 21 日
